Dyadic International (NASDAQ:DYAI) is a biotechnology company focused on developing, manufacturing, and commercializing a wide range of biologic products. Utilizing its proprietary C1-cell protein production platform, Dyadic aims to create efficient and cost-effective biopharmaceuticals for industrial, animal, and human health applications. Projects include developing vaccines, monoclonal antibodies, and other therapeutic proteins. Dyadic's ultimate objective is to improve health standards globally by making biologic vaccines and drugs more accessible and affordable to healthcare systems and patients around the world.